io102

Vaccineexperimental

Clinical trial activity

6 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
6
Phase 3
1
Phase 4
0

Earliest trial started Aug 22, 2018 (NCT03562871)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05977907Phase 2Dec 1, 2023IO Biotech, Johns Hopkins University, Merck
NCT05912244Phase 2Jun 9, 2023IO Biotech, Memorial Sloan-Kettering Cancer Center
NCT05155254Phase 3Dec 31, 2021Almac Clinical Services LLC, IO Biotech, Klifo A/S, Merck, Syneos Health, University of Copenhagen
NCT05077709Phase 2Oct 31, 2021Almac Clinical Services LLC, IO Biotech, NeoGenomics Laboratories, Theradex, University of California, Davis
NCT04445064Phase 2Aug 14, 2020Université catholique de Louvain
NCT03562871Phase 1/Phase 2 (Phase 2)Aug 22, 2018IO Biotech, Merck, University of London
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
IO BiotechFor profit5322018
MerckFor profit3022018
Almac Clinical Services LLCFor profit2022021
Johns Hopkins UniversityAcademic/Hospital1112023
Klifo A/SFor profit1012021
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1112023
NeoGenomics LaboratoriesFor profit1012021
Syneos HealthFor profit1012021
TheradexFor profit1012021
Université catholique de LouvainAcademic/Hospital1112020
University of California, DavisAcademic/Hospital1012021
University of CopenhagenAcademic/Hospital1012021
University of LondonAcademic/Hospital1012018
13 organizations
Page 1 / 1